Sana Biotechnology
SANA
155 hedge funds and large institutions have $639M invested in Sana Biotechnology in 2024 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 42 increasing their positions, 45 reducing their positions, and 24 closing their positions.
52% more call options, than puts
Call options by funds: $9.77M | Put options by funds: $6.42M
33% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 24
5% more funds holding
Funds holding: 148 → 155 (+7)
1.99% more ownership
Funds ownership: 66.95% → 68.94% (+2%)
7% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 45
21% less capital invested
Capital invested by funds: $810M → $639M (-$171M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.3M |
| 2 |
BlackRock
New York
|
+$4.05M |
| 3 |
IHAM
Integral Health Asset Management
New York
|
+$3.15M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.92M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$6.22M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$1.54M |
| 3 |
Two Sigma Investments
New York
|
-$1.4M |
| 4 |
Citigroup
New York
|
-$1.31M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.2M |
SANA Hedge Fund Activity: Q3 2024 in Review
155 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Sana Biotechnology (SANA) for Q3 2024, worth a combined $639M — down 21% from $810M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new SANA positions and 24 closed out — a net gain of 8 holders — while 42 added to existing stakes and 45 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $23.3M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $6.22M.
- 155 institutional investors held Sana Biotechnology (SANA) as of Q3 2024, up from 148 in Q2 2024.
- Funds reported $639M of Sana Biotechnology stock for Q3 2024, down 21% quarter-over-quarter.
- 32 funds opened new Sana Biotechnology positions in Q3 2024 and 24 closed out, a net change of +8 holders.
- The largest Sana Biotechnology buyer in Q3 2024 was Fidelity Investments, an estimated $23.3M added.
- The largest Sana Biotechnology seller in Q3 2024 was T. Rowe Price Investment Management, an estimated $6.22M sold.
Based on aggregated 13F filings for Q3 2024.